anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
NEW MATERIAL:A compound shown by formula I [R is methyl or methoxy; X is methylene, ethylene or carbonyl; R1 is 5,6-dimethoxy-3-methyl-1,4- benzoquinolyl, group shown by formula II (R2 is H, phenyl or benzyl), etc.] and a salt thereof. EXAMPLE:2,3-Dimethoxy-5-methyl-6-(4-phenylpiperidyl)dimethyl-1,4-benzo quinone. USE:Having inhibitory action on blood platelet aggregation, positive intropic action, relaxing action on blood vessel, eliminating action on active enzyme seeds, etc., useful for treating arteriosclerosis, cerebral infarct, cardiac incompe tence, angina pectoris, dementia, arrhythmia, peptic ulcer, etc. PREPARATION:A compound shown by formula III is reacted with a compound shown by formula H-R9 (R9 is group shown by formula II) in the presence of formaldehyde to give a hydroquinone derivative shown by formula IV. Then the reaction product is oxidized with an oxidizing agent such as ferric chloride to give a compound shown by formula I.
PROBLEM TO BE SOLVED: To simply and readily provide a person with a healthy and young impression by vertically dividing a face into specific two parts in prescribed shapes, selecting specified cosmetics for each part and making up each part. SOLUTION: A face is vertically divided into two parts. Cosmetics are selected so as to make the lightness of the makeup cosmetic of the upper part higher than that of the makeup cosmetic of the lower part. The boundary line to vertically divide the face into the two parts is preferably laid between lines connecting both bottom parts of ears to an upper lip and lines connecting both top parts of ear root parts to the bottom part of a nose as an up-and-down dividing line. The lightness is differed at the up and down part and the upper part is made up lightly and is provided with a young and bright image. The difference in the lightness is 0.05-0.5, especially 0.07-0.4, more preferably about 0.1-0.3 as the value of Munsell color coordinate.  A method for presetting the color of a foundation of the whole face and applying a foundation for a part to be shaded to the lower part of the face or a highlight for a part to be lightened to the upper part of the face may be used as the method for makeup.
PURPOSE: Acute heart failure (AHF) syndromes manifest increased inflammation and vascular dysfunction; however, mechanisms that integrate the two in AHF remain largely unknown. The glycocalyx (GAC) is a sugar-based shell that envelops all mammalian cells. Much GAC research has focused on its role in vascular responses, with comparatively little known about how the GAC regulates immune cell function.
METHODS: In this study, we sought to determine if GAC degradation products are elevated in AHF patients, how these degradation products relate to circulating inflammatory mediators, and whether the monocyte GAC (mGAC) itself modulates monocyte activation. Inflammatory markers and GAC degradation products were profiled using ELISAs. Flow cytometry was used to assess the mGAC and RNA-seq was employed to understand the role of the mGAC in regulating inflammatory activation programs.
RESULTS: In a cohort of hospitalized AHF patients (n = 17), we found that (1) the GAC degradation product heparan sulfate (HS) was elevated compared with age-matched controls (4396 and 2903 ng/mL; p = 0.01) and that (2) HS and soluble CD14 (a marker of monocyte activation) levels were closely related (Pearson's r = 0.65; p = 0.002). Mechanistically, Toll-like receptor (TLR) activation of human monocytes results in GAC remodeling and a decrease in the mGAC (71% compared with no treatment; p = 0.0007). Additionally, we found that ex vivo enzymatic removal of HS and disruption of the mGAC triggers human monocyte activation and amplifies monocyte inflammatory responses. Specifically, using RNA-seq, we found that enzymatic degradation of the mGAC increases transcription of inflammatory (IL6, CCL3) and vascular (tissue factor/F3) mediators.
CONCLUSION: These studies indicate that the mGAC is dynamically remodeled during monocyte activation and that mGAC remodeling itself may contribute to the heightened inflammation associated with AHF.
Naltrexone is a medication currently used to treat opiate dependence. Naltrexone blocks the euphoric effects of opiates. However, naltrexone treatment suffers from high rates of drop-out and relapse. One possible explanation for this is that opiate addicts continue to experience stress in early recovery from opiate dependence. Lofexidine is an experimental medication currently used in the United Kingdom for opiate detoxification and to treat opiate withdrawal symptoms, including sleep difficulty, muscle pain, anxiety, and tension. The purpose of this study is to examine whether lofexidine in combination with naltrexone can improve an individual's ability to cope with stress. The study will examine whether this, in turn, increases the likelihood that an individual remains abstinent from opiates and maintains recovery for a longer time period.

Participants in this 12-week, double-blind, placebo-controlled trial will be randomly assigned to receive either lofexidine or placebo while currently receiving standard naltrexone outpatient treatment. Lofexidine will be initiated at twice daily doses of 0.4 mg and increased to 0.8 mg by the end of Week 1. The doses will be increased to 1.2 mg by the end of Week 2, and maintained at this level for Weeks 3 through 12. During Week 12, lofexidine discontinuation will be tapered over 4 days. Hour-long study visits will occur 3 times each week to assess vital signs, medication side effects, and withdrawal symptoms. Blood, alcohol, and urine tests will be performed as well as a psychiatric evaluation. Administration of naltrexone will also occur 3 times each week. Follow-up visits will occur at Months 1 and 3 after discontinuation of lofexidine.
Milrinone lactate is a member of a class of bipyridine inotropic/vasodilator agents with phosphodiesterase inhibitor activity, distinct from digitalis glycosides or catecholamines. Milrinone lactate is designated chemically as 1,6-dihydro-2-methyl-6-oxo-[3,4’-bipyridine]-5-carbonitrile lactate and has the following structure:

Milrinone is an off-white to tan crystalline compound with a molecular weight of 211.2 and a molecular formula of C12H9N3O. It is slightly soluble in methanol, and very slightly soluble in chloroform and in water.

As the lactate salt, it is stable and colorless to pale yellow in solution. Milrinone lactate is available as sterile aqueous solutions of the lactate salt of milrinone for injection or infusion intravenously.

Sterile, Single Dose Vials: Single dose vials of 10, 20 and 50 mL contain in each mL milrinone lactate equivalent to 1 mg milrinone and 47 mg Dextrose Anhydrous, USP, in Water for Injection, USP. The pH is adjusted to between 3.2 and 4.0 with lactic acid or sodium hydroxide. The total concentration of lactic acid can vary between 0.95 mg/mL and 1.29 mg/mL. These vials require preparation of dilutions prior to administration to patients intravenously.
To understand the effect of the addition of colesevelam HCl to oral agent therapy in individuals with type 2 diabetes on glycemic control by utilizing a novel technology, continuous glucose monitoring with ambulatory glucose profile analysis. To date there are no studies of this compound that have employed continuous glucose monitoring (CGM) with ambulatory glucose profile (AGP) analysis to obtain data that will detail the diurnal glucose patterns associated with this therapy. We plan to employ CGM at critical points throughout the study. AGP analysis will enable rapid assessment of the clinical status of the subject. Using statistically stable estimates of hourly values represented by five percentile curves AGP depicts glucose exposure, variability and stability. Previously, we have used AGP analysis to characterize glucose perturbations in individuals ranging from normal glucose tolerance to overt type 2 diabetes.
The target is to evaluate the effect of the administration of Gymnema Sylvestre on glycemic control, insulin secretion and insulin sensibility on patients with IGT. The investigators will conduct a double-blind trial, randomized, placebo control group, each group 12 female and male patients, between 30 and 59 years old with IGT (2-h values in the oral glucose tolerance test, OGTT) from 140 mg / dL to 199 mg / dL), Body Mass Index (BMI) from 25 to 34.9 kg / m2. Randomization will determine who will receive the intervention during the 9-week trial (Gymnema Sylvestre capsules, 300 mg 2 times daily with the first bite of breakfast and dinner or homologated placebo capsules). The clinical findings and laboratory tests include a metabolic profile and biosafety, which will be made at baseline and at week 9. Body weight, body fat, BMI and blood pressure will be determined during the initial and final visit. Adverse events and adherence to treatment will be documented. Statistical analysis: Mann-Whitney U test, Wilcoxon and Fisher exact test. It is considered with significance at p \<0.05.
Gait disorders are a common feature of neurological disease. The gait examination is an essential part of the neurological clinical assessment, providing valuable clues to a myriad of causes. Understanding how to examine gait is not only essential for neurological diagnosis but also for treatment and prognosis. Here, we review aspects of the clinical history and examination of neurological gait to help guide gait disorder assessment. We focus particularly on how to differentiate between common gait abnormalities and highlight the characteristic features of the more prevalent neurological gait patterns such as ataxia, waddling, steppage, spastic gait, Parkinson's disease and functional gait disorders. We also offer diagnostic clues for some unusual gait presentations, such as dystonic, stiff-person and choreiform gait, along with red flags that help differentiate atypical parkinsonism from Parkinson's disease.
The primary objective of the study is to determine the radiographic response rate in patients with metastatic colorectal cancer treated with Oxaliplatin, Capecitabine and Irinotecan. Secondary objectives are to determine the time to tumor progression and the toxicity and tolerability of Oxaliplatin, Capecitabine and Irinotecan when administered in combination. Study schema is as follows. Cycles are 42 days long. Patients will receive Oxaliplatin and Capecitabine on day 1. Capecitabine is an oral pill that will be taken for 14 days. Patients return again on day 21 when they receive Irinotecan and Capecitabine. Capecitabine again is taken for 14 days. CT scans are performed at the end of the 6 week cycle to determine response.
The method for assessing the efficacy of the regeneration of the injured peripheral nerve stimulated by lipoflavone at the late stage in experiment comprises the examination of the nervous tissues. The standard model of the injury of peripheral nerve is reproduced. Then lipoflavone, lipin, and corvitine are administered paraneurally for ten days. In 12 weeks, the samples are taken for ultrastructural study. The density of the nerve fibers and the angle of their deviation from the axis of the injured nerve are determined. The results are compared with control. The decreased degeneration of the nerves and blood vessels as well as the decreased fibrosis in the injured nerve are indicative of the efficacy of the regeneration of the injured peripheral nerve stimulated by lipoflavone at the late stage in experiment.
Before the local anesthesia injection, patients will be asked to give a preliminary VAS score based on what level of pain 0-10 they anticipate they will feel during the local anesthesia injection. Following the injection the participant will be asked to quantify the pain felt during the injection on a 0-10 Visual analog scale (VAS). The VAS scores will only be taken from the first injection of the appointment. Participants will be asked their gender, race, age, geographic location they spent most of their lives as well. Participants will be de-identified and randomly assigned a number that will be recorded along with their collected data on a two-factor, password protected web server. Information collected during this study may be used for further analysis and publication.
HYLENEX recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in HYLENEX recombinant. A preliminary skin test for hypersensitivity to HYLENEX recombinant can be performed. The skin test is made by an intradermal injection of approximately 0.02 mL (3 Units) of a 150 Unit/mL solution. A positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. Transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. Discontinue HYLENEX recombinant if sensitization occurs.
The invention belongs to the technical field of traditional Chinese medicine and discloses a traditional Chinese medicine enema mixture. The traditional Chinese medicine enema mixture is mainly prepared from chrysanthemum, isatis root, nutgrass galingale rhizome, tree peony bark, zedoary rhizome, light yellow sophora root and Amur Corktree Bark according to a certain compatible relationship. Preferably, the traditional Chinese medicine enema mixture is mainly prepared from chrysanthemum, isatis root, nutgrass galingale rhizome, tree peony bark, zedoary rhizome, light yellow sophora root, Amur Corktree Bark, capa jasmine and indigowoad leaf according to a certain compatible relationship. More preferably, the traditional Chinese medicine enema mixture is mainly prepared from chrysanthemum, isatis root, nutgrass galingale rhizome, tree peony bark, zedoary rhizome, light yellow sophora root, Amur Corktree Bark, capa jasmine, indigowoad leaf and danshen root according to a certain compatible relationship. The traditional Chinese medicine enema mixture is simple in preparation process, and safe without any toxic and side effects. Clinically experimental verification proves that the traditional Chinese medicine enema mixture has the advantages of quick effect taking and high effective rate in the treatment of gynecological diseases such as chronic pelvic inflammation and vaginitis, and the gynecological diseases do not relapse after being cured.
TAK-981 at RP2D as determined in Phase 1b. Mezagitamab at a fixed dose of 600 mg SC injection or Daratumumab and Hyaluronidase-fihj at a fixed dose of 1800 mg weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycle 3 through 6, followed by every 4 weeks up to Cycle 24 or until disease progression unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
SCOPE: Cinnamaldehyde (CAH), a phytochemical constituent isolated from cinnamon, is gaining attention due to its nutritional and medicinal benefits. This study aimed to investigate the potential role of CAH in the treatment of ulcerative colitis (UC).
METHODS AND RESULTS: Integrated metabolomics and gut microbiome analysis are performed for 2,4,6-trinitrobenzenesulfonic acid (TNBS) induced UC rats. The effect of CAH on colonic inflammation, lipid peroxidation, metabolic profiles, and gut microbiota is systematically explored. It finds that CAH improves the colitis-related symptoms, decreases disease activity index, increases the colon length and body weight, and alleviates histologic inflammation of UC rats. These therapeutic effects of CAH are due to suppression of inflammation and lipid peroxidation. Moreover, multi-omics analysis reveals that CAH treatment cause changes in plasma metabolome and gut microbiome in UC rats. CAH regulates lipid metabolic processes, especially phosphatidylcholines, lysophosphatidylcholines, and polyunsaturated fatty acids. Meanwhile, CAH modulates the gut microbial structure by restraining pathogenic bacteria (such as Helicobacter) and increasing probiotic bacteria (such as Bifidobacterium and Lactobacillus).
CONCLUSIONS: These results indicate that CAH exerts a beneficial role in UC by synergistic modulating the balance in gut microbiota and the associated metabolites, and highlights the nutritional and medicinal value of CAH in UC management.
The invention provides a traditional Chinese medicine preparation used for treating childbed fever. Childbed fever belongs to disease category of postpartum fever in traditional Chinese medicine, and is caused by evil toxin external infection, and blood stasis and blood deficiency. The traditional Chinese medicine is prepared by subjecting Galium verum L., Rubus buergeri Miq. Root, Viola inconspicua Bl., Dolichos lablab L., Cratoxylon ligustrinum (Spach) Blume., Salvia plebeian, abrus cantoniensis hance, Tecomaria capensis (Thunb.)Spach, Disporopsis fuscopicta Hance, camellia flower, and Erigeron breviscapus hand.-Mazz. to water decoction so as to obtain a decoction. It is confirmed by clinical experiments that total effective rate is 95%, and is obvious higher than that of a control group.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to surgery and radiation diagnostics, and can be used to select surgical approach to anterior mediastinum in patients with thymus tumors using preoperative computed tomographic angiography of the breast. Division of the mediastinum into the floors is carried out by tomograms in the frontal projection using two conditional vertical lines passing through the sternoclavicular joints, and two conditional horizontal lines passing through V and VIII thoracic vertebrae. If the tumor has a diameter of up to 8 cm in the upper floor of the mediastinum, including a right shift relative to the right sternoclavicular joint,/diameter and more, right-sided thoracoscopic approach is used. If the tumor is localized with diameter of up to 8 cm in the upper floor of the mediastinum with a left shift relative to the left sternoclavicular joint at/diameter and more – left-sided thoracoscopic approach. If the tumor is localized with diameter of up to 8 cm and displaced to the middle floor of mediastinum/diameter and more – video-assisted combined access consisting of sub-xyphoid and transthoracic. If tumor diameter is more than 8 cm in the upper and middle floors of mediastinum without CT signs of invasion of neighboring anatomical structures, right-sided thoracotomy is used in absence of tumor displacement or right- or left-sided thoracotomy depending on tumor displacement to the right or to left on/diameter and more relative to sternoclavicular joints. If observing CT signs of tumor invasion of any diameter in adjacent anatomical structures, combined thoracic sternotomy is used.EFFECT: method provides reduced duration of surgical intervention, intraoperative blood loss, number of complications, length of hospital stay by visualization of anatomical structures of mediastinum by means of contrast agent, improved scheme of dividing the mediastinum into floors by tomograms in frontal projection.1 cl, 8 dwg, 1 ex
Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
Participants with racial and ethnic minorities, including Black or African American participants, with newly diagnosed AL amyloidosis will receive SC injection of daratumumab 1800 mg SC on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] either orally or intravenously \[IV\], bortezomib 1.3 mg/m\^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
This is a prospective, randomized study designed to evaluate if CRT device optimization, guided by electrocardiography, improves cardiac function and clinical outcomes among patients considered non-responders to CRT. All patients will have electrocardiographic assessment of electrical dyssynchrony at a range of device settings using standard ECG machines. All patients will then have a baseline CMR study at baseline CRT programming, underlying rhythm, and optimal settings derived from the electrocardiographic assessment to assess acute effects of CRT optimization on mechanical synchrony, LV regional wall motion, and LV structure/ function. To assess chronic effects of CRT optimization, patients will be randomized in a 1:1 ratio after baseline CMR to either the active comparator arm (baseline CRT programming), or the experimental arm (CRT device programmed to optimal settings derived from the electrocardiographic assessment). Patients will be blinded to randomization. After 6 month, all patients will return for follow up CMR study to assess chronic effects. After follow up CMR imaging, the active comparator group will crossover to the experimental group. After 12 months, all patients will return for follow up echocardiogram to further evaluate the chronic effects of CRT optimization.
PCT No. PCT/HU90/00020 Sec. 371 Date Dec. 20, 1990 Sec. 102(e) Date Dec. 20, 1990 PCT Filed Mar. 21, 1990 PCT Pub. No. WO90/11143 PCT Pub. Date Oct. 4, 1990.The invention relates to an environment-protective agent consisting of silicon-containing minerals for adsorbing radiactive metal isotopes and toxic heavy metals, which comprises as silicon-containing minerals with a particle size of 0.001 to 0.5 mm; a natural diatomaceous earth and at least two natural zeolite minerals of the general formula MxO.Al2O3.YSiO2.7H2O wherein M stands for sodium, potassium or calcium; x is a number between 1 and 2 inclusive of both extreme values; Y is 3 or 10; and Z is 6 or 7 treated by dilute acid, washed to neutral, dried to a constant weight at a temperature up to 115 DEG 0 C. and then heat-treated at 150 DEG  to 350 DEG  C., preferably at 250 DEG  C., where the amount of each mineral ingredient independently of each other is at least 0.1% by weight up to 99.8% by weight calculated to the total weight of the agent. The invention further relates to pharmaceutical compositions and animal foods containing the above agent according to the invention as active ingredient.